Gavin R Screaton

List of Publications by Year
in descending order

97 papers	17,127 citations	29994 54 h-index	35952 97 g-index
165 all docs	165 docs citations	165 times ranked	22900 citing authors

#	Article	IF	Citations
1	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	7.0	1,066
2	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
3	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
4	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature Immunology, 2016, 17, 1102-1108.	7.0	781
5	Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans. Science, 2010, 328, 745-748.	6.0	780
6	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature Medicine, 2003, 9, 921-927.	15.2	707
7	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	13.5	630
8	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	13.5	532
9	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
10	Structural basis of potent Zikaâ€“dengue virus antibody cross-neutralization. Nature, 2016, 536, 48-53.	13.7	465
11	T Cell Responses to Whole SARS Coronavirus in Humans. Journal of Immunology, 2008, 181, 5490-5500.	0.4	449
12	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	13.5	442
13	MAIT cells are activated during human viral infections. Nature Communications, 2016, 7, 11653.	5.8	428
14	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nature Immunology, 2015, 16, 170-177.	7.0	415
15	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infectious Diseases, The, 2020, 20, 1390-1400.	4.6	336
16	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	13.5	331
17	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet, The, 2022, 399, 234-236.	6.3	318
18	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet, The, 2022, 399, 521-529.	6.3	314

#	Article	IF	Citations
19	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature, 2015, 520, 109-113.	13.7	301
20	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host and Microbe, 2020, 28, 445-454.e6.	5.1	298
21	New insights into the immunopathology and control of dengue virus infection. Nature Reviews Immunology, 2015, 15, 745-759.	10.6	282
22	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural and Molecular Biology, 2020, 27, 950-958.	3.6	268
23	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262
24	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nature Structural Biology, 1999, 6, 1048-1053.	9.7	235
25	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clinical Infectious Diseases, 2021, 73, e699-e709.	2.9	235
26	Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor Î¶ Chain. Journal of Experimental Medicine, 1999, 189, 1489-1496.	4.2	231
27	Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16922-16927.	3.3	215
28	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
29	Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. ELife, 2020, 9, .	2.8	196
30	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
31	Antibody testing for COVID-19: A report from theÂNational COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	0.9	179
32	An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection. Journal of Virology, 2011, 85, 410-421.	1.5	165
33	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	6.3	161
34	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine, 2022, 28, 1072-1082.	15.2	147
35	Antibodies and tuberculosis. Tuberculosis, 2016, 101, 102-113.	0.8	131
36	The immune response against flaviviruses. Nature Immunology, 2018, 19, 1189-1198.	7.0	126

#	Article	IF	Citations
37	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. Journal of Infectious Diseases, 2018, 218, 536-545.	1.9	124
38	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	5.3	118
39	Cardiovascular manifestations of the emerging dengue pandemic. Nature Reviews Cardiology, 2014, 11, 335-345.	6.1	110
40	An immunodominant NP105â€“113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	7.0	110
41	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
42	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	104
43	HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor. Journal of Experimental Medicine, 2004, 200, 1547-1557.	4.2	103
44	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
45	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nature Immunology, 2017, 18, 1261-1269.	7.0	95
46	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nature Communications, 2021, 12, 6250.	5.8	88
47	Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity. Journal of Immunology, 2012, 188, 4971-4979.	0.4	82
48	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	81
49	Complex Regulation of Tau Exon 10, Whose Missplicing Causes Frontotemporal Dementia. Journal of Neurochemistry, 2001, 74, 490-500.	2.1	80
50	Convalescent plasma therapy for the treatment of patients with COVIDâ€19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine, 2021, 31, 167-175.	0.5	71
51	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nature Communications, 2017, 8, 15411.	5.8	69
52	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441.	5.8	69
53	Sensing of Immature Particles Produced by Dengue Virus Infected Cells Induces an Antiviral Response by Plasmacytoid Dendritic Cells. PLoS Pathogens, 2014, 10, e1004434.	2.1	65
54	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clinical Infectious Diseases, 2022, 74, 1208-1219.	2.9	64

#	Article	IF	Citations
55	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	3.9	64
56	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nature Immunology, 2019, 20, 1291-1298.	7.0	60
57	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
58	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host and Microbe, 2022, 30, 53-68.e12.	5.1	52
59	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nature Medicine, 2018, 24, 721-723.	15.2	46
60	A Simplified Positive-Sense-RNA Virus Construction Approach That Enhances Analysis Throughput. Journal of Virology, 2013, 87, 12667-12674.	1.5	44
61	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. Journal of Infection, 2022, 84, 795-813.	1.7	43
62	Recent advances in understanding dengue. F1000Research, 2016, 5, 78.	0.8	40
63	Recent advances in human flavivirus vaccines. Current Opinion in Virology, 2017, 23, 95-101.	2.6	39
64	The immunopathology of dengue and Zika virus infections. Current Opinion in Immunology, 2017, 48, 1-6.	2.4	38
65	The epitope arrangement on flavivirus particles contributes to Mab C10â€™s extraordinary neutralization breadth across Zika and dengue viruses. Cell, 2021, 184, 6052-6066.e18.	13.5	38
66	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. Nature Communications, 2021, 12, 1238.	5.8	37
67	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. Nature Immunology, 2017, 18, 1228-1237.	7.0	36
68	Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. Journal of Leukocyte Biology, 2017, 101, 775-783.	1.5	33
69	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Nature Immunology, 2018, 19, 1248-1256.	7.0	31
70	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. Nature Communications, 2020, 11, 5278.	5.8	30
71	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
72	Microvascular and endothelial function for risk prediction in dengue: an observational study. Lancet, The, 2015, 385, S102.	6.3	24

#	Article	IF	Citations
73	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. Journal of Virology, 2018, 92, .	1.5	24
74	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	2.3	24
75	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respiratory Medicine,the, 2022, 10, 1049-1060.	5.2	24
76	Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study. Clinical Infectious Diseases, 2017, 65, 1453-1461.	2.9	23
77	Autoantibody-dependent amplification of inflammation in SLE. Cell Death and Disease, 2020, 11, 729.	2.7	23
78	Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infectious Diseases, 2021, 21, 187.	1.3	23
79	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	2.7	23
80	Invariant NKT Cell Response to Dengue Virus Infection in Human. PLoS Neglected Tropical Diseases, 2014, 8, e2955.	1.3	21
81	High flavivirus structural plasticity demonstrated by a non-spherical morphological variant. Nature Communications, 2020, 11, 3112.	5.8	19
82	The immunology of Zika Virus. F1000Research, 2018, 7, 203.	0.8	18
83	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. Cell Reports, 2019, 26, 1585-1597.e4.	2.9	18
84	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. Vaccines, 2020, 8, 307.	2.1	18
85	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Eurosurveillance, 2020, 25, .	3.9	17
86	T cell Responses and Dengue Haemorrhagic Fever. Novartis Foundation Symposium, 2008, , 164-176.	1.2	16
87	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029520.	2.3	16
88	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	16
89	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. Novartis Foundation Symposium, 2008, , 149-157.	1.2	11
90	Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics. Cell, 2021, 184, 6067-6080.e13.	13.5	11

#	Article	IF	Citations
91	T cell responses and dengue haemorrhagic fever. Novartis Foundation Symposium, 2006, 277, 164-71; discussion 171-6, 251-3.	1.2	11
92	HIV-1 Nef: negative effector of Fas?. Nature Immunology, 2001, 2, 384-385.	7.0	8
93	Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. MSphere, 2022, 7, e0091321.	1.3	8
94	Evolution of neurovirulent Zika virus. Science, 2017, 358, 863-864.	6.0	7
95	Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. Frontiers in Immunology, 2018, 9, 1621.	2.2	7
96	SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection. Nature Communications, 2022, 13, .	5.8	6
97	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2